Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

PHASE3CompletedINTERVENTIONAL
Enrollment

193

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Hematologic DiseasesAnemia, Sickle Cell
Interventions
DRUG

Hydroxyurea

Participants will receive hydroxyurea.

DRUG

Placebo

Participants will receive placebo.

Trial Locations (14)

11203

SUNY Health Science Center, Brooklyn, Brooklyn

19134

Drexel University, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20060

Howard University, Washington D.C.

21287

Johns Hopkins University, Baltimore

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

30342

Emory University School of Medicine, Atlanta

33136

University of Miami, Miami

35233

University of Alabama at Birmingham, Birmingham

38105

St. Jude Children's Research Hospital, Memphis

39216

University of Mississippi Medical Center, Jackson

48201

Children's Hospital of Michigan/Wayne State Univ., Detroit

75390

University of Texas SW Medical Center, Dallas

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00006400 - Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | Biotech Hunter | Biotech Hunter